Allos Therapeutics
Latest round
- Series A
Last raised
- Jun 1995
Total raised
- $3M
Investors
- 3
About Allos Therapeutics
Allos Therapeutics focuses on utilizing Causal AI technology to forecast clinical intervention outcomes, targeting unmet needs in the pharmaceutical sector.Allos Therapeutics, founded in 1992, is based in Westminster, US, and specializes in innovative approaches for clinical drug development. The company underwent a significant transition when it was acquired by Spectrum Pharmaceuticals in September 2012.Allos specializes in Causal AI technology, which enables the forecasting of clinical intervention effects on patient outcomes, distinguishing it from traditional AI, which primarily focuses on inference. The company's core offerings include a robust platform that identifies and revitalizes complex generic drugs, thereby addressing unmet patient needs within the pharmaceutical landscape. This data-driven approach allows Allos to optimize clinical development pathways effectively, making drug innovations safer, faster, and more cost-efficient.Allos generates revenue through strategic partnerships and licensing agreements with pharmaceutical companies and healthcare providers. The transaction structure primarily focuses on B2B engagements, where clients may access Allos’ Causal AI platform via subscription models or through fixed contracts for specific projects. This allows clients to leverage the technology for drug development and optimization in a manner tailored to their operational needs. Specific pricing plans and flagship services are aligned with the complexity and scale of the projects undertaken, ensuring that Allos' offerings remain accessible to a broad range of clientele while maximizing the value delivered to its partners.Allos Therapeutics plans to enhance its product offerings with new developments in its Causal AI technology, aiming to launch new tools for drug optimization in the next two years. Additionally, the company is targeting expansion into emerging markets in Asia and South America by 2025, capitalizing on the growing demand for innovative generics in these regions.
Who invested in Allos Therapeutics
3 investors across 1 round
See all investors in Allos Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 1, 1995
Amount
$3M
Investors
Questions about Allos Therapeutics
Who invested in Allos Therapeutics?
Allos Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Allos Therapeutics raised?
Allos Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Allos Therapeutics last raise money?
Allos Therapeutics's most recent round on record is a Series A, in Jun 1995.
What does Allos Therapeutics do?
Allos Therapeutics focuses on utilizing Causal AI technology to forecast clinical intervention outcomes, targeting unmet needs in the pharmaceutical sector.
Where is Allos Therapeutics headquartered?
Allos Therapeutics is headquartered in Westminster, US.
Which VCs invest in companies like Allos Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Allos Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Allos Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.